{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+and+sham+treatment&page=62",
    "query": {
      "intervention": "Placebo and sham treatment",
      "page": 62
    },
    "page_size": 10
  },
  "pagination": {
    "page": 62,
    "page_size": 10,
    "total_count": 27795,
    "total_pages": 2780,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+and+sham+treatment&page=63&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+and+sham+treatment&page=61&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-25T22:23:19.858Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01558115",
      "title": "Denosumab in Primary Hyperparathyroidism",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Primary Hyperparathyroidism"
      ],
      "interventions": [
        {
          "name": "Denosumab",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Columbia University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "40 Years and older · Female only"
      },
      "enrollment_count": 8,
      "start_date": "2012-01",
      "completion_date": "2014-10",
      "has_results": true,
      "last_update_posted_date": "2022-11-02",
      "last_synced_at": "2026-10-25T22:23:19.858Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01558115"
    },
    {
      "nct_id": "NCT02658435",
      "title": "Assessment of Any Potential Retinal Effects of Tafenoquine (TQ)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Malaria, Vivax"
      ],
      "interventions": [
        {
          "name": "Tafenoquine 150 mg",
          "type": "DRUG"
        },
        {
          "name": "Matched placebo 150mg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "18 Years to 45 Years"
      },
      "enrollment_count": 486,
      "start_date": "2016-02-02",
      "completion_date": "2017-09-14",
      "has_results": false,
      "last_update_posted_date": "2018-03-01",
      "last_synced_at": "2026-10-25T22:23:19.858Z",
      "location_count": 3,
      "location_summary": "Glendale, California • Overland Park, Kansas • Baltimore, Maryland",
      "locations": [
        {
          "city": "Glendale",
          "state": "California"
        },
        {
          "city": "Overland Park",
          "state": "Kansas"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02658435"
    },
    {
      "nct_id": "NCT02835235",
      "title": "A Trial Investigating Safety, Tolerability, PK and PD for Multiple Doses of NNC9204-0530 in Male and Female Subjects Being Overweight or With Obesity",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Metabolism and Nutrition Disorder",
        "Obesity"
      ],
      "interventions": [
        {
          "name": "NNC9204-0530",
          "type": "DRUG"
        },
        {
          "name": "placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novo Nordisk A/S",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 48,
      "start_date": "2016-07-26",
      "completion_date": "2017-07-07",
      "has_results": false,
      "last_update_posted_date": "2018-01-08",
      "last_synced_at": "2026-10-25T22:23:19.858Z",
      "location_count": 2,
      "location_summary": "Tempe, Arizona • Lincoln, Nebraska",
      "locations": [
        {
          "city": "Tempe",
          "state": "Arizona"
        },
        {
          "city": "Lincoln",
          "state": "Nebraska"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02835235"
    },
    {
      "nct_id": "NCT06511908",
      "title": "Investigation of the Antidepressant Effects of (2R,6R)-HNK, an Enhancer of Synaptic Glutamate Release, in Treatment-Resistant Depression",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Suicide",
        "Depressive Disorder, Treatment-Resistant",
        "Ketamine",
        "Molecular Mechanisms of Pharmacological Action",
        "Neurotransmitter Agents",
        "Excitatory Amino Acid Agents",
        "Physiological Effects of Drugs",
        "Depressive Disorder, Major",
        "Depressive Disorder",
        "Depression",
        "Mental Disorders",
        "Mood Disorders",
        "Behavioral Symptoms"
      ],
      "interventions": [
        {
          "name": "(2R,6R)-hydroxynorketamine (0.25 to 2.0 mg/kg)",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Institute of Mental Health (NIMH)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 50,
      "start_date": "2024-11-06",
      "completion_date": "2027-07-01",
      "has_results": false,
      "last_update_posted_date": "2026-10-05",
      "last_synced_at": "2026-10-25T22:23:19.858Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06511908"
    },
    {
      "nct_id": "NCT00398125",
      "title": "Monotherapy Versus Placebo Over 10 Days in Integrase Naive HIV-1 Infected Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Infection, Human Immunodeficiency Virus",
        "HIV-1 Infection"
      ],
      "interventions": [
        {
          "name": "GSK364735",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 30,
      "start_date": "2006-11",
      "completion_date": "2007-04",
      "has_results": false,
      "last_update_posted_date": "2012-07-30",
      "last_synced_at": "2026-10-25T22:23:19.858Z",
      "location_count": 12,
      "location_summary": "Birmingham, Alabama • Los Angeles, California • San Diego, California + 9 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00398125"
    },
    {
      "nct_id": "NCT03032640",
      "title": "Interactions of Human Gut Microbiota With Intestinal Sweet Taste Receptors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Obesity"
      ],
      "interventions": [
        {
          "name": "Oral Glucose Tolerance Test (OGTT)",
          "type": "OTHER"
        },
        {
          "name": "Assessment of dietary compliance",
          "type": "OTHER"
        },
        {
          "name": "Stool sampling",
          "type": "OTHER"
        },
        {
          "name": "Sodium Saccharin",
          "type": "OTHER"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        },
        {
          "name": "Lactisole",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "AdventHealth Translational Research Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "18 Years to 45 Years"
      },
      "enrollment_count": 102,
      "start_date": "2017-01-26",
      "completion_date": "2022-10-18",
      "has_results": false,
      "last_update_posted_date": "2023-02-02",
      "last_synced_at": "2026-10-25T22:23:19.858Z",
      "location_count": 1,
      "location_summary": "Orlando, Florida",
      "locations": [
        {
          "city": "Orlando",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03032640"
    },
    {
      "nct_id": "NCT02182440",
      "title": "A Safety, Tolerability, Efficacy and QoL Study of Human recAP in the Treatment of Patients With SA-AKI",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Acute Kidney Injury"
      ],
      "interventions": [
        {
          "name": "recAP",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "AM-Pharma",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "18 Years to 85 Years"
      },
      "enrollment_count": 301,
      "start_date": "2014-12-18",
      "completion_date": "2017-09-27",
      "has_results": true,
      "last_update_posted_date": "2020-03-23",
      "last_synced_at": "2026-10-25T22:23:19.858Z",
      "location_count": 6,
      "location_summary": "Birmingham, Alabama • Tampa, Florida • Idaho Falls, Idaho + 3 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Idaho Falls",
          "state": "Idaho"
        },
        {
          "city": "Cincinnati",
          "state": "Ohio"
        },
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02182440"
    },
    {
      "nct_id": "NCT00156689",
      "title": "A Study to Determine if Levetiracetam Will Assist Those Suffering From Chronic Idiopathic Axonal Polyneuropathy.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Chronic Idiopathic Axonal Polyneuropathy"
      ],
      "interventions": [
        {
          "name": "levetiracetam",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Vanderbilt University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 30,
      "start_date": "2005-08",
      "completion_date": "2007-05",
      "has_results": false,
      "last_update_posted_date": "2008-01-11",
      "last_synced_at": "2026-10-25T22:23:19.858Z",
      "location_count": 1,
      "location_summary": "Nashville, Tennessee",
      "locations": [
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00156689"
    },
    {
      "nct_id": "NCT02442778",
      "title": "Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Agitation in Participants With Dementia of the Alzheimer's Type",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Agitation in Participants With Dementia of the Alzheimer's Type"
      ],
      "interventions": [
        {
          "name": "AVP-786-18",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "AVP-786-28",
          "type": "DRUG"
        },
        {
          "name": "AVP-786-42.63",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Otsuka Pharmaceutical Development & Commercialization, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": "90 Years",
        "sex": "ALL",
        "summary": "50 Years to 90 Years"
      },
      "enrollment_count": 522,
      "start_date": "2015-11-11",
      "completion_date": "2019-09-09",
      "has_results": true,
      "last_update_posted_date": "2022-09-09",
      "last_synced_at": "2026-10-25T22:23:19.858Z",
      "location_count": 79,
      "location_summary": "Chandler, Arizona • Tucson, Arizona • Fayetteville, Arkansas + 55 more",
      "locations": [
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Fayetteville",
          "state": "Arkansas"
        },
        {
          "city": "Glendale",
          "state": "California"
        },
        {
          "city": "Irvine",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02442778"
    },
    {
      "nct_id": "NCT00324155",
      "title": "Dacarbazine and Ipilimumab vs. Dacarbazine With Placebo in Untreated Unresectable Stage III or IV Melanoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Melanoma"
      ],
      "interventions": [
        {
          "name": "Ipilimumab",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Dacarbazine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bristol-Myers Squibb",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 681,
      "start_date": "2006-08",
      "completion_date": "2013-10",
      "has_results": true,
      "last_update_posted_date": "2014-11-03",
      "last_synced_at": "2026-10-25T22:23:19.858Z",
      "location_count": 32,
      "location_summary": "Anaheim, California • La Verne, California • Los Angeles, California + 28 more",
      "locations": [
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "La Verne",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Palm Springs",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00324155"
    }
  ]
}